Bereich
Brustzentrum St.Gallen
BZ · Dept. IV
Axillary Surgery in Breast Cancer - Primary Results of the INSEMA Trial.
Reimer T, Stachs A, Veselinovic K, Kühn T, Heil J, Polata S, Marme F, Müller T, Hildebrandt G, Krug D, Ataseven B, Reitsamer R, Ruth S, Denkert C, Bekes I, Zahm D, Thill M, Golatta M, Holtschmidt J, Knauer M, Nekljudova V, Loibl S, Gerber B. Axillary Surgery in Breast Cancer - Primary Results of the INSEMA Trial. N Engl J Med 2024
12.12.2024Axillary Surgery in Breast Cancer - Primary Results of the INSEMA Trial.
12.12.2024N Engl J Med 2024
Reimer Toralf, Stachs Angrit, Veselinovic Kristina, Kühn Thorsten, Heil Jörg, Polata Silke, Marme Frederik, Müller Thomas F, Hildebrandt Guido, Krug David, Ataseven Beyhan, Reitsamer Roland, Ruth Sylvia, Denkert Carsten, Bekes Inga, Zahm Dirk-Michael, Thill Marc, Golatta Michael, Holtschmidt Johannes, Knauer Michael, Nekljudova Valentina, Loibl Sibylle, Gerber Bernd
Molecular adaptation to neoadjuvant immunotherapy in triple-negative breast cancer.
Denkert C, Schneeweiss A, Rey J, Karn T, Hattesohl A, Weber K, Rachakonda S, Braun M, Huober J, Jank P, Sinn H, Zahm D, Felder B, Hanusch C, Teply-Szymanski J, Marme F, Fehm T, Thomalla J, Sinn B, Stiewe T, Marczyk M, Blohmer J, van Mackelenbergh M, Schem C, Staib P, Link T, Müller V, Stickeler E, Stover D, Solbach C, Metzger-Filho O, Jackisch C, Geyer C, Fasching P, Pusztai L, Nekljudova V, Untch M, Loibl S. Molecular adaptation to neoadjuvant immunotherapy in triple-negative breast cancer. Cell Rep Med 2024; 5:101825.
19.11.2024Molecular adaptation to neoadjuvant immunotherapy in triple-negative breast cancer.
19.11.2024Cell Rep Med 2024; 5:101825
Denkert Carsten, Schneeweiss Andreas, Rey Julia, Karn Thomas, Hattesohl Akira, Weber Karsten E, Rachakonda Sivaramakrishna, Braun Michael, Huober Jens, Jank Paul, Sinn Hans-Peter, Zahm Dirk-Michael, Felder Bärbel, Hanusch Claus, Teply-Szymanski Julia, Marme Frederik, Fehm Tanja N, Thomalla Jörg, Sinn Bruno Valentin, Stiewe Thorsten, Marczyk Michal, Blohmer Jens-Uwe, van Mackelenbergh Marion T, Schem Christian, Staib Peter, Link Theresa, Müller Volkmar, Stickeler Elmar, Stover Daniel G, Solbach Christine, Metzger-Filho Otto, Jackisch Christian, Geyer Charles E, Fasching Peter Andreas, Pusztai Lajos, Nekljudova Valentina, Untch Michael, Loibl Sibylle
On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer.
Sinn B, Sychra K, Untch M, Karn T, van Mackelenbergh M, Huober J, Schmitt W, Marme F, Schem C, Solbach C, Stickeler E, Tesch H, Fasching P, Schneeweiss A, Müller V, Holtschmidt J, Nekljudova V, Loibl S, Denkert C. On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer. Breast Cancer Res 2024; 26:138.
24.09.2024On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer.
24.09.2024Breast Cancer Res 2024; 26:138
Sinn Bruno Valentin, Sychra Katharina, Untch Michael, Karn Thomas, van Mackelenbergh Marion T, Huober Jens, Schmitt Wolfgang Daniel, Marme Frederik, Schem Christian, Solbach Christine, Stickeler Elmar, Tesch Hans, Fasching Peter Andreas, Schneeweiss Andreas, Müller Volkmar, Holtschmidt Johannes, Nekljudova Valentina, Loibl Sibylle, Denkert Carsten
GAIN2 trial overall survival with intense versus tailored dose dense chemotherapy in early breast cancer.
Möbus V, Lück H, Ladda E, Klare P, Engels K, Schmidt M, Schneeweiss A, Grischke E, Wachsmann G, Forstbauer H, Untch M, Marme F, Blohmer J, Jackisch C, Huober J, Stickeler E, Reinisch M, Link T, Sinn B, Janni W, Denkert C, Seiler S, Solbach C, Schmatloch S, Rey J, Loibl S. GAIN2 trial overall survival with intense versus tailored dose dense chemotherapy in early breast cancer. NPJ Breast Cancer 2024; 10:66.
30.07.2024GAIN2 trial overall survival with intense versus tailored dose dense chemotherapy in early breast cancer.
30.07.2024NPJ Breast Cancer 2024; 10:66
Möbus Volker, Lück Hans-Joachim, Ladda Ekkehart, Klare Peter, Engels Knut, Schmidt Marcus, Schneeweiss Andreas, Grischke Eva-Maria, Wachsmann Grischa, Forstbauer Helmut, Untch Michael, Marme Frederik, Blohmer Jens-Uwe, Jackisch Christian, Huober Jens, Stickeler Elmar, Reinisch Mattea, Link Theresa, Sinn Bruno Valentin, Janni Wolfgang, Denkert Carsten, Seiler Sabine, Solbach Christine, Schmatloch Sabine, Rey Julia, Loibl Sibylle
An analysis of PIK3CA hotspot mutations and response to neoadjuvant therapy in breast cancer patients from four prospective clinical trials.
Jank P, Karn T, van Mackelenbergh M, Lindner J, Treue D, Huober J, Engels K, Solbach C, Diebold K, Marme F, Müller V, Schneeweiss A, Sinn H, Fehm T, Schem C, Stickeler E, Fasching P, Budczies J, Felder B, Nekljudova V, Holtschmidt J, Untch M, Denkert C, Loibl S. An analysis of PIK3CA hotspot mutations and response to neoadjuvant therapy in breast cancer patients from four prospective clinical trials. Clin Cancer Res 2024
05.06.2024An analysis of PIK3CA hotspot mutations and response to neoadjuvant therapy in breast cancer patients from four prospective clinical trials.
05.06.2024Clin Cancer Res 2024
Jank Paul, Karn Thomas, van Mackelenbergh Marion T, Lindner Judith L, Treue Denise, Huober Jens, Engels Knut, Solbach Christine, Diebold Kurt, Marme Frederik, Müller Volkmar, Schneeweiss Andreas, Sinn Hans-Peter, Fehm Tanja N, Schem Christian, Stickeler Elmar, Fasching Peter Andreas, Budczies Jan, Felder Bärbel, Nekljudova Valentina, Holtschmidt Johannes, Untch Michael, Denkert Carsten, Loibl Sibylle
Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3.
Goetz M, Toi M, Huober J, Sohn J, Trédan O, Park I, Campone M, Chen S, Manso L, Paluch-Shimon S, Freedman O, O'Shaughnessy J, Pivot X, Tolaney S, Hurvitz S, Llombart-Cussac A, Andre V, Saha A, van Hal G, Shahir A, Iwata H, Johnston S. Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3. Ann Oncol 2024
08.05.2024Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3.
08.05.2024Ann Oncol 2024
Goetz Matthew P, Toi Masakazu, Huober Jens, Sohn Joo Hyuk, Trédan Olivier, Park In Hae, Campone Mario, Chen S-C, Manso L M, Paluch-Shimon Shani, Freedman Orit C, O'Shaughnessy Joyce, Pivot X, Tolaney Sara M, Hurvitz Sara A, Llombart-Cussac Antonio, Andre Valerie A M, Saha A, van Hal G, Shahir Ashwin, Iwata H, Johnston Stephen R D
Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study.
Goetz M, Cicin I, Testa L, Tolaney S, Huober J, Guarneri V, Johnston S, Martín M, Rastogi P, Harbeck N, Shahir A, Wei R, Andre V, Rugo H, O'Shaughnessy J. Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study. NPJ Breast Cancer 2024; 10:34.
26.04.2024Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study.
26.04.2024NPJ Breast Cancer 2024; 10:34
Goetz Matthew P, Cicin Irfan, Testa Laura, Tolaney Sara M, Huober Jens, Guarneri Valentina, Johnston Stephen R D, Martín Miguel, Rastogi Priya, Harbeck Nadia, Shahir Ashwin, Wei Ran, Andre Valerie A M, Rugo Hope S, O'Shaughnessy Joyce
Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE).
Meyer-Wilmes P, Huober J, Untch M, Blohmer J, Janni W, Denkert C, Klare P, Link T, Rhiem K, Bayer C, Reinisch M, Bjelic-Radisic V, Zahm D, Hanusch C, Solbach C, Heinrich G, Hartkopf A, Schneeweiss A, Fasching P, Filmann N, Nekljudova V, Holtschmidt J, Stickeler E, Loibl S. Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE). ESMO Open 2024; 9:103009.
24.04.2024Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE).
24.04.2024ESMO Open 2024; 9:103009
Meyer-Wilmes P, Huober Jens, Untch Michael, Blohmer J-U, Janni Wolfgang, Denkert Carsten, Klare Peter, Link Theresa, Rhiem Kerstin, Bayer C, Reinisch Mattea, Bjelic-Radisic Vesna, Zahm Dirk Michael, Hanusch Claus, Solbach Christine, Heinrich Georg, Hartkopf Andreas D, Schneeweiss Andreas, Fasching Peter Andreas, Filmann N, Nekljudova Valentina, Holtschmidt J, Stickeler Elmar, Loibl Sibylle
Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2024.
Park-Simon T, Müller V, Albert U, Banys-Paluchowski M, Bauerfeind I, Blohmer J, Budach W, Dall P, Ditsch N, Fallenberg E, Fasching P, Fehm T, Friedrich M, Gerber B, Gluz O, Harbeck N, Hartkopf A, Heil J, Huober J, Jackisch C, Kolberg-Liedtke C, Kreipe H, Krug D, Kühn T, Kümmel S, Loibl S, Luftner D, Lux M, Maass N, Mundhenke C, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn H, Solbach C, Solomayer E, Stickeler E, Thomssen C, Untch M, Witzel I, Wuerstlein R, Wöckel A, Janni W, Thill M. Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2024. Breast Care (Basel) 2024; 19:165-182.
18.04.2024Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2024.
18.04.2024Breast Care (Basel) 2024; 19:165-182
Park-Simon Tjoung-Won, Müller Volkmar, Albert Ute-Susann, Banys-Paluchowski Maggie, Bauerfeind Ingo, Blohmer Jens-Uwe, Budach Wilfried, Dall Peter, Ditsch Nina, Fallenberg Eva Maria, Fasching Peter Andreas, Fehm Tanja N, Friedrich Michael, Gerber Bernd, Gluz Oleg, Harbeck Nadia, Hartkopf Andreas Daniel, Heil Jörg, Huober Jens, Jackisch Christian, Kolberg-Liedtke Cornelia, Kreipe Hans-Heinrich, Krug David, Kühn Thorsten, Kümmel Sherko, Loibl Sibylle, Luftner Diana, Lux Michael Patrick, Maass Nicolai, Mundhenke Christoph, Reimer Toralf, Rhiem Kerstin, Rody Achim, Schmidt Marcus, Schneeweiss Andreas, Schütz Florian, Sinn Hans-Peter, Solbach Christine, Solomayer Erich-Franz, Stickeler Elmar, Thomssen Christoph, Untch Michael, Witzel Isabell, Wuerstlein Rachel, Wöckel Achim, Janni Wolfgang, Thill Marc
Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2024.
Thill M, Janni W, Albert U, Banys-Paluchowski M, Bauerfeind I, Blohmer J, Budach W, Dall P, Ditsch N, Fallenberg E, Fasching P, Fehm T, Friedrich M, Gerber B, Gluz O, Harbeck N, Hartkopf A, Heil J, Huober J, Jackisch C, Kolberg-Liedtke C, Kreipe H, Krug D, Kühn T, Kümmel S, Loibl S, Luftner D, Lux M, Maass N, Mundhenke C, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn H, Solbach C, Solomayer E, Stickeler E, Thomssen C, Untch M, Witzel I, Wöckel A, Wuerstlein R, Müller V, Park-Simon T. Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2024. Breast Care (Basel) 2024; 19:183-191.
10.04.2024Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2024.
10.04.2024Breast Care (Basel) 2024; 19:183-191
Thill Marc, Janni Wolfgang, Albert Ute-Susann, Banys-Paluchowski Maggie, Bauerfeind Ingo, Blohmer Jens-Uwe, Budach Wilfried, Dall Peter, Ditsch Nina, Fallenberg Eva Maria, Fasching Peter Andreas, Fehm Tanja N, Friedrich Michael, Gerber Bernd, Gluz Oleg, Harbeck Nadia, Hartkopf Andreas D, Heil Jörg, Huober Jens, Jackisch Christian, Kolberg-Liedtke Cornelia, Kreipe Hans-Heinrich, Krug David, Kühn Thorsten, Kümmel Sherko, Loibl Sibylle, Luftner Diana, Lux Michael Patrick, Maass Nicolai, Mundhenke Christoph, Reimer Toralf, Rhiem Kerstin, Rody Achim, Schmidt Marcus, Schneeweiss Andreas, Schütz Florian, Sinn Hans-Peter, Solbach Christine, Solomayer Erich-Franz, Stickeler Elmar, Thomssen Christoph, Untch Michael, Witzel Isabell, Wöckel Achim, Wuerstlein Rachel, Müller Volkmar, Park-Simon Tjoung-Won
Baseline CD4 and expansion of γδ T cells correlate with response to durvalumab in triple-negative breast cancer patients.
Massa C, Karn T, Weber K, Schneeweiss A, Hanusch C, Blohmer J, Zahm D, Jackisch C, van Mackelenbergh M, Thomalla J, Marme F, Huober J, Müller V, Schem C, Mueller A, Stickeler E, Biehl K, Fasching P, Untch M, Loibl S, Denkert C, Seliger B. Baseline CD4 and expansion of γδ T cells correlate with response to durvalumab in triple-negative breast cancer patients. Clin Transl Med 2024; 14:e1617.
01.04.2024Baseline CD4 and expansion of γδ T cells correlate with response to durvalumab in triple-negative breast cancer patients.
01.04.2024Clin Transl Med 2024; 14:e1617
Massa Chiara, Karn Thomas, Weber Karsten E, Schneeweiss Andreas, Hanusch Claus, Blohmer Jens-Uwe, Zahm Dirk-Michael, Jackisch Christian, van Mackelenbergh Marion T, Thomalla Jörg, Marme Frederik, Huober Jens, Müller Volkmar, Schem Christian, Mueller Anja, Stickeler Elmar, Biehl Katharina, Fasching Peter Andreas, Untch Michael, Loibl Sibylle, Denkert Carsten, Seliger Barbara
Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials.
Fernandez-Martinez A, Rediti M, Tang G, Pascual T, Hoadley K, Venet D, Rashid N, Spears P, Islam N, El-Abed S, Bliss J, Lambertini M, Di Cosimo S, Huober J, Goerlitz D, Hu R, Lucas P, Swain S, Sotiriou C, Perou C, Carey L. Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials. JAMA Oncol 2024
28.03.2024Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials.
28.03.2024JAMA Oncol 2024
Fernandez-Martinez Aranzazu, Rediti Mattia, Tang Gong, Pascual Tomás, Hoadley Katherine A, Venet David, Rashid Naim U, Spears Patricia A, Islam N, El-Abed Sarra, Bliss Judith, Lambertini Matteo, Di Cosimo Serena, Huober Jens, Goerlitz David, Hu Rong, Lucas Peter C, Swain Sandra M, Sotiriou Christos, Perou Charles M, Carey Lisa A
Radiotherapy statements of the 18th St. Gallen International Breast Cancer Consensus Conference-a German expert perspective.
Krug D, Banys-Paluchowski M, Brucker S, Denkert C, Ditsch N, Fasching P, Haidinger R, Harbeck N, Heil J, Huober J, Jackisch C, Janni W, Kolberg H, Loibl S, Luftner D, van Mackelenbergh M, Radosa J, Reimer T, Welslau M, Wuerstlein R, Untch M, Budach W. Radiotherapy statements of the 18th St. Gallen International Breast Cancer Consensus Conference-a German expert perspective. Strahlenther Onkol 2024
23.02.2024Radiotherapy statements of the 18th St. Gallen International Breast Cancer Consensus Conference-a German expert perspective.
23.02.2024Strahlenther Onkol 2024
Krug David, Banys-Paluchowski Maggie, Brucker Sara Y, Denkert Carsten, Ditsch Nina, Fasching Peter Andreas, Haidinger Renate, Harbeck Nadia, Heil Jörg, Huober Jens, Jackisch Christian, Janni Wolfgang, Kolberg Hans-Christian, Loibl Sibylle, Luftner Diana, van Mackelenbergh Marion T, Radosa Julia C, Reimer Toralf, Welslau Manfred, Wuerstlein Rachel, Untch Michael, Budach Wilfried
Is Pertuzumab Plus Trastuzumab Without Chemotherapy a Reasonable Treatment for ERBB2-Positive Metastatic Breast Cancer?-Reply.
Huober J, Thürlimann B, Dietrich D. Is Pertuzumab Plus Trastuzumab Without Chemotherapy a Reasonable Treatment for ERBB2-Positive Metastatic Breast Cancer?-Reply. JAMA Oncol 2024
08.02.2024Is Pertuzumab Plus Trastuzumab Without Chemotherapy a Reasonable Treatment for ERBB2-Positive Metastatic Breast Cancer?-Reply.
08.02.2024JAMA Oncol 2024
Huober Jens, Thürlimann Beat, Dietrich Daniel
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes.
Rastogi P, O'Shaughnessy J, Martín M, Boyle F, Cortes J, Rugo H, Goetz M, Hamilton E, Huang C, Senkus E, Tryakin A, Cicin I, Testa L, Neven P, Huober J, Shao Z, Wei R, Andre V, Munoz M, San Antonio B, Shahir A, Harbeck N, Johnston S. Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes. J Clin Oncol 2024:JCO2301994.
09.01.2024Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes.
09.01.2024J Clin Oncol 2024:JCO2301994
Rastogi Priya, O'Shaughnessy Joyce, Martín Miguel, Boyle Frances, Cortes Javier, Rugo Hope S, Goetz Matthew P, Hamilton Erika, Huang Chiun-Sheng, Senkus Elzbieta, Tryakin Alexey, Cicin Irfan, Testa Laura, Neven Patrick, Huober Jens, Shao Zhimin, Wei Ran, Andre Valerie A M, Munoz Maria, San Antonio Belen, Shahir Ashwin, Harbeck Nadia, Johnston Stephen R D
Efficacy of Lapatinib in Patients with HER2-Negative Metastatic Breast Cancer and HER2-Positive Circulating Tumor Cells-The DETECT III Clinical Trial.
Fehm T, Müller V, Banys-Paluchowski M, Fasching P, Friedl T, Hartkopf A, Huober J, Loehberg C, Rack B, Riethdorf S, Schneeweiss A, Wallwiener D, Meier-Stiegen F, Krawczyk N, Jaeger B, Reinhardt F, Hoffmann O, Müller L, Wimberger P, Ruckhäberle E, Blohmer J, Cieslik J, Franken A, Niederacher D, Neubauer H, Pantel K, Janni W, DETECT study group. Efficacy of Lapatinib in Patients with HER2-Negative Metastatic Breast Cancer and HER2-Positive Circulating Tumor Cells-The DETECT III Clinical Trial. Clin Chem 2024; 70:307-318.
04.01.2024Efficacy of Lapatinib in Patients with HER2-Negative Metastatic Breast Cancer and HER2-Positive Circulating Tumor Cells-The DETECT III Clinical Trial.
04.01.2024Clin Chem 2024; 70:307-318
Fehm Tanja N, Müller Volkmar, Banys-Paluchowski Maggie, Fasching Peter Andreas, Friedl Thomas Wolfram Paul, Hartkopf Andreas D, Huober Jens, Loehberg Christian R, Rack Brigitte, Riethdorf Sabine, Schneeweiss Andreas, Wallwiener Diethelm, Meier-Stiegen Franziska, Krawczyk Natalia, Jaeger Bernadette, Reinhardt Florian, Hoffmann Oliver, Müller Lothar, Wimberger Pauline, Ruckhäberle Eugen, Blohmer Jens-Uwe, Cieslik Jan-Philipp, Franken André, Niederacher Dieter, Neubauer Hans, Pantel Klaus, Janni Wolfgang, DETECT study group
Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer.
Fasching P, Decker T, Hartkopf A, Nusch A, Heinrich B, Kurbacher C, Fuchs R, Tesch H, Krabisch P, Huober J, Kümmel S, Brucker S, Janni W, Schneeweiss A, Schuler M, Fehm T, Luftner D, Quiering C, Voges C, Kreuzeder J, Reinisch M. Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer. Eur J Cancer 2023; 198:113480.
15.12.2023Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer.
15.12.2023Eur J Cancer 2023; 198:113480
Fasching Peter Andreas, Decker Thomas, Hartkopf Andreas D, Nusch Arnd, Heinrich Bernhard J, Kurbacher Christian M, Fuchs Roswitha, Tesch Hans, Krabisch Petra, Huober Jens, Kümmel Sherko, Brucker Sara Y, Janni Wolfgang, Schneeweiss Andreas, Schuler Martin, Fehm Tanja N, Luftner Diana, Quiering Claudia, Voges Claudia, Kreuzeder Julia, Reinisch Mattea
ASO Visual Abstract: Minimally-Invasive Breast Biopsy After Neoadjuvant Systemic Treatment to Identify Breast Cancer Patients with Residual Disease for Extended Neoadjuvant Treatment-A New Concept.
Pfob A, Cai L, Schneeweiss A, Rauch G, Thomas B, Schaefgen B, Kümmel S, Reimer T, Hahn M, Thill M, Blohmer J, Hackmann J, Malter W, Bekes I, Friedrichs K, Wojcinski S, Joos S, Paepke S, Degenhardt T, Rom J, Rody A, van Mackelenbergh M, Banys-Paluchowski M, Große R, Reinisch M, Karsten M, Sidey-Gibbons C, Wallwiener M, Golatta M, Heil J. ASO Visual Abstract: Minimally-Invasive Breast Biopsy After Neoadjuvant Systemic Treatment to Identify Breast Cancer Patients with Residual Disease for Extended Neoadjuvant Treatment-A New Concept. Ann Surg Oncol 2023
13.12.2023ASO Visual Abstract: Minimally-Invasive Breast Biopsy After Neoadjuvant Systemic Treatment to Identify Breast Cancer Patients with Residual Disease for Extended Neoadjuvant Treatment-A New Concept.
13.12.2023Ann Surg Oncol 2023
Pfob André, Cai Lie, Schneeweiss Andreas, Rauch Geraldine, Thomas Bettina, Schaefgen Benedikt, Kümmel Sherko, Reimer Toralf, Hahn Markus, Thill Marc, Blohmer Jens-Uwe, Hackmann John, Malter Wolfram, Bekes Inga, Friedrichs Kay, Wojcinski Sebastian, Joos Sylvie, Paepke Stefan, Degenhardt Tom, Rom Joachim, Rody Achim, van Mackelenbergh Marion T, Banys-Paluchowski Maggie, Große Regina, Reinisch Mattea, Karsten Maria Margarete, Sidey-Gibbons Chris, Wallwiener Markus, Golatta Michael, Heil Jörg
SAKK57/16 Nab-paclitaxel and Gemcitabine in Soft Tissue Sarcoma (NAPAGE): a phase I/II trial.
Digklia A, Kollár A, Felber Dietrich D, Kronig M, Britschgi C, Rordorf T, Jörger M, Krasniqi F, Metaxas Y, Colombo I, Ribi K, Rothermundt C. SAKK57/16 Nab-paclitaxel and Gemcitabine in Soft Tissue Sarcoma (NAPAGE): a phase I/II trial. Eur J Cancer 2023; 197:113470.
09.12.2023SAKK57/16 Nab-paclitaxel and Gemcitabine in Soft Tissue Sarcoma (NAPAGE): a phase I/II trial.
09.12.2023Eur J Cancer 2023; 197:113470
Digklia Antonia, Kollár Attila, Felber Dietrich Denise, Kronig M N, Britschgi Christian, Rordorf Tamara, Jörger Markus, Krasniqi Fatime, Metaxas Yannis, Colombo Ilaria, Ribi Karin, Rothermundt Christian
CMR reveals myocardial damage from cardiotoxic oncologic therapies in breast cancer patients.
Kersten J, Fink V, Kersten M, May L, Nunn S, Tadic M, Huober J, Bekes I, Radermacher M, Hombach V, Rottbauer W, Buckert D. CMR reveals myocardial damage from cardiotoxic oncologic therapies in breast cancer patients. Int J Cardiovasc Imaging 2023
25.11.2023CMR reveals myocardial damage from cardiotoxic oncologic therapies in breast cancer patients.
25.11.2023Int J Cardiovasc Imaging 2023
Kersten Johannes, Fink Visnja, Kersten Maria, May Lisa, Nunn Samuel, Tadic Marijana, Huober Jens, Bekes Inga, Radermacher Michael, Hombach Vinzenz, Rottbauer Wolfgang, Buckert Dominik